Details for Patent: 11,433,046

Which drugs does patent 11,433,046 protect, and when does it expire?

Patent 11,433,046 protects EPRONTIA and is included in one NDA.

Summary for Patent: 11,433,046

Patent landscape, scope, and claims:

Title:	Compositions and methods for treating epilepsy, seizures and other conditions
Abstract:	Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
Inventor(s):	Tu; Yu-Hsing (West Windsor, NJ), Perumal; Ashok (Monmouth Junction, NJ), Kathala; Kalyan (Monroe, NJ), Bhattacharya; Romona (Franklin Park, NJ)
Assignee:	Tulex Pharmaceuticals Inc. (Cranbury, NJ)
Application Number:	17/308,910
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device;

Drugs Protected by US Patent 11,433,046

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	EPRONTIA	topiramate	SOLUTION;ORAL	214679-001	Nov 5, 2021	AB	RX	Yes	Yes						INDICATED AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF PARTIAL-ONSET SEIZURES, PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, AND SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
Azurity	EPRONTIA	topiramate	SOLUTION;ORAL	214679-001	Nov 5, 2021	AB	RX	Yes	Yes						INDICATED AS INITIAL MONOTHERAPY FOR THE TREATMENT OF PARTIAL-ONSET OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 2 YEARS OF AGE AND OLDER
Azurity	EPRONTIA	topiramate	SOLUTION;ORAL	214679-001	Nov 5, 2021	AB	RX	Yes	Yes						INDICATED FOR THE PREVENTIVE TREATMENT OF MIGRAINE IN PATIENTS 12 YEARS AND OLDER